Streetwise Reports' Article Archives — Current Month (5)
US$12 Billion RNA Deal Triggers Sector Shakeup (11/14/2025)
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
Preclinical Compounds Perform Better Than Existing Drugs (11/13/2025)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.
Lead Drug Faces Uncertain FDA Path After Phase 3 Miss (11/13/2025)
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.
Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials (11/12/2025)
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.
Clean Tech Finds Massive Energy Savings in PFAS Treatment (11/05/2025)
BioLargo Inc. (BLGO:OTCQX) announces a significant upgrade to its patented Aqueous Electrostatic Concentrator (AEC) system, reducing energy consumption by over 90% in large-scale "forever chemical" treatment for drinking water.
More Archives
2025Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
